Polarityte, INC.: management transactions · United States · SEC (Form 4)

About Polarityte, INC.

POLARITYTE, INC. is a biotechnology company listed on NASDAQ in the United States (United States) and headquartered in Salt Lake City, Utah. Founded in 2016, the company was built around a regenerative-medicine platform focused on developing tissue products and biomaterials intended to support human tissue repair and regeneration. In market terms, PolarityTE remains a highly specialized small-cap biotech with a concentrated strategy centered on wound care, skin reconstruction, and broader regenerative tissue applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1076682/000149315219000547/form10-k.htm?utm_source=openai)) The company’s best-known program is SkinTE®, its first regenerative tissue product. SEC disclosures describe SkinTE as intended for the repair, reconstruction, replacement, and regeneration of skin in patients with acute or chronic wounds, burns, surgical reconstruction needs, scar revision, or dysfunctional skin graft issues. Public filings also indicate that PolarityTE maintains manufacturing processes and quality systems in Salt Lake City to receive tissue specimens, process them, and perform quality control before shipment. That operational footprint underscores the company’s vertically oriented, product-development-heavy model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1076682/000149315222008097/form10-k.htm?utm_source=openai)) From a competitive standpoint, PolarityTE operates in a niche but potentially attractive corner of healthcare, at the intersection of advanced wound care, cell/tissue engineering, and biomaterials. However, it is also a highly regulated segment in which commercial success depends on clinical evidence, FDA pathways, and manufacturing compliance. The SEC materials reviewed show that the company pursued an IND pathway for SkinTE and planned pivotal studies to support a future BLA for a chronic cutaneous ulcer indication. That makes the investment case inherently binary and catalyst-driven, with a much higher risk profile than that of a diversified commercial-stage medtech or pharma company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1076682/000149315222008097/form10-k.htm?utm_source=openai)) Geographically, the business is primarily U.S.-centric. Its headquarters, manufacturing, and core development activities are in Utah, and its public-market identity is tied to the U.S. NASDAQ listing. For French-, Belgian-, and Swiss-based investors, the key issue is not international scale but whether the company can advance its regulatory program, maintain adequate funding, and convert scientific promise into a durable commercial franchise in the domestic U.S. market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1076682/000149315219000547/form10-k.htm?utm_source=openai)) Recent public developments point more to financing and corporate restructuring than to large-scale commercialization: PolarityTE announced capital raises in 2022, a 1-for-25 reverse stock split in May 2022, and earlier communications referenced strategic and regulatory updates around SkinTE as well as the conclusion of an SEC investigation. Overall, the company should be viewed as a speculative small-cap biotech whose valuation is likely to be driven by regulatory milestones, clinical progress, and financing execution rather than near-term operating scale. ([nasdaq.com](https://www.nasdaq.com/press-release/polarityte-announces-%248.0-million-registered-direct-and-private-placement-offerings?utm_source=openai))